The migraine market has been a somewhat static space for nearly two decades, dominated by over-the-counter products and a dominant class that went generic. More recent launches and near-term candidates tend to be reformulations of existing drug classes, such as triptans and ergotamine, though there are some antibody therapies mostly in early- to mid-stage development. But those companies see significant opportunity in the space.
Migraine headaches comprise really two indications – treatment of acute migraine headaches in patients who have anywhere from one to...